ClinicalTrials.gg
CompletedNCT00688987Updated Jun 5, 2008

The Hypothalamic-Pituitary-Adrenal (HPA) Axis as an Effector System in Weight Regulation

An interventional study of Hydrocortisone and Isocaloric Diet in Obesity and Addison's Disease, sponsored by Oregon Health and Science University. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2008-06-05.

Sponsored by Oregon Health and Science University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Replacing glucocorticoid in a dose dependent manner (including doses within the physiological range) to subjects with adrenal insufficiency will increase visceral fat accumulation independently of total fat mass.

Read the detailed description

To measure total fat mass by DEXA scan, central (visceral) fat accumulation, insulin sensitivity by FSIVGTT, lipid levels, and adipocyte gene expression in subjects with AI receiving increasing doses of hydrocortisone replacement (15 mg, 25 mg, and 40 mg per day in split doses) for 4-months at a time during ad-lib feeding.

02

Conditions studied

  • Obesity
  • Addison's Disease
03

In context

Obesity

6,570 studies on the registry are indexed under Obesity; 1,718 are open to participants now.

This study's enrollment of 24 is below the median of 77 across 5,084 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Oregon Health and Science University is the lead sponsor of 694 studies on the registry; 133 are open to participants now.

Of its 51 completed or terminated interventional studies of FDA-regulated products, 39 (76%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects with complete adrenal failure as defined as spontaneous serum cortisol of levels less than 5 g/dl after 12 hours without glucocorticoid replacement and peak serum cortisol of \< 5 g/dl 60 minutes after a 250 g ACTH stimulation test.
  • Subjects who are at their usual weight (weight stable for at least 1 year)
  • Subjects on stable replacement doses of any required hormone such as thyroid, sex hormones, mineralocorticoid replacement, growth hormone, and hydrocortisone for at least 6 months, and 4) have a normal body weight (BMI 19-27 kg/m2).

Exclusion criteria

Exclusion Criteria:

  • Possible confounders on body weight and insulin resistance
  • Age less than 18 to exclude those who might be experiencing alterations in cortisol production or weight as a result of adolescent growth.
  • Subjects who exercise > 30 minutes/day, 3 times a week.
  • Smokers.
  • Heavy alcohol drinkers (> 2 drinks/ day).
  • Subjects with medical diagnosis including diabetes, heart disease, and cancer.
  • Subjects with psychiatric illness (i.e., depression, psychosis, bipolar, schizophrenia; or are taking medications for these disorders).
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
24 participants (actual)

Study arms

  • Active comparator
    1

    Subjects with AI will be randomized to each of three doses of hydrocortisone for 4 months on each dose.

    Drug: Hydrocortisone

  • Active comparator
    2

    isocaloric diet

    Dietary Supplement: Isocaloric Diet

Interventions

  • Subjects will receive in random order daily (split) dosing of hydrocortisone: a low dose of 15 mg (10 in AM, 5 in PM); a medium dose of 25 mg (15 in AM, 10 in PM) and high dose of 40 mg (30 in AM, 10 in PM) for 4 months.

  • Dietary supplementIsocaloric Diet

    Subjects will eat an isocaloric diet for 4 weeks while taking hydrocortisone

    Also known as: Weight stable diet

06

What researchers measure

Primary outcomes

  1. Amounts of intra-abdominal fat and total fat at the end of the treatment period for each cortisol dose.

    Time frame: After 4 months on each dose

Secondary outcomes

  1. Fasting Lipid levels, fat mass by DEXA, post-heparin lipase activity, insulin sensitivity, and fat biopsy

    Time frame: After 4-months on each dose

07

Study locations

1 site
  • Oregon Health & Science University
    Portland, Oregon 97239, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2000, a primary completion of Jul 2004 and a completion of Aug 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 30, 2008
First posted
Jun 3, 2008
Start
Aug 2000
Primary completionActual
Jul 2004
CompletionActual
Aug 2004
Last update
Jun 5, 2008
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00688987
First posted
Jun 3, 2008
Start date
Aug 2000
Primary completion
Jul 2004
Completion
Aug 2004
Last update
Jun 5, 2008

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Hydrocortisone

Start the discussion